Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, December 31, 2021.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2021 (2021-12-31): -625.73%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-166.93%
RETURN ON EQUITY (ROE) AVG 3Y
-59.53%
RETURN ON EQUITY (ROE) AVG 5Y
-47.06%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Minerva Neurosciences, Inc.
Market Cap
$158.40M
Return on Equity (ROE)
N/A
TTM Avg
-166.93%
3Y Avg
-59.53%
5Y Avg
-47.06%
Market Cap
$157.03M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$155.86M
Return on Equity (ROE)
N/A
TTM Avg
13.51%
3Y Avg
15.58%
5Y Avg
15.05%
Market Cap
$155.68M
Return on Equity (ROE)
-170.49%
TTM Avg
-166.01%
3Y Avg
-121.36%
5Y Avg
-104.96%
Market Cap
$161.16M
Return on Equity (ROE)
-60.19%
TTM Avg
-68.34%
3Y Avg
-61.91%
5Y Avg
-47.91%
Market Cap
$161.45M
Return on Equity (ROE)
-215.26%
TTM Avg
-150.35%
3Y Avg
8.65%
5Y Avg
-35.35%
Market Cap
$163.27M
Return on Equity (ROE)
-51.90%
TTM Avg
-23.95%
3Y Avg
-20.95%
5Y Avg
-18.62%
Market Cap
$152.73M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$151.65M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | $158.40M | N/A | -166.93% | -59.53% | -47.06% |
| Inogen, Inc. (INGN)vs › | $157.03M | -14.07% | -16.23% | -27.66% | -19.01% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | 13.51% | 15.58% | 15.05% |
| Neuronetics, Inc. (STIM)vs › | $155.68M | -170.49% | -166.01% | -121.36% | -104.96% |
| PepGen Inc. (PEPG)vs › | $161.16M | -60.19% | -68.34% | -61.91% | -47.91% |
| Coherus Oncology, Inc. (CHRS)vs › | $161.45M | -215.26% | -150.35% | 8.65% | -35.35% |
| Quanterix Corporation (QTRX)vs › | $163.27M | -51.90% | -23.95% | -20.95% | -18.62% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $152.73M | -59.40% | -255.06% | -160.44% | -112.56% |
| Codexis, Inc. (CDXS)vs › | $151.65M | -93.22% | -92.28% | -73.94% | -53.80% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | -155.34% | -168.75% | -117.97% | -104.46% |
ROE
N/A
ROA
-414.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2021-12-31 | -625.73% |
| 2021-09-30 | -127.94% |
| 2021-06-30 | -96.30% |
| 2021-03-31 | 11.65% |
| 2020-12-31 | 3.68% |
| 2020-09-30 | -35.59% |
| 2020-06-30 | -46.54% |
| 2020-03-31 | -367.84% |
| 2019-12-31 | -259.84% |
| 2019-09-30 | -99.89% |
| 2019-06-30 | -79.57% |
| 2019-03-31 | -69.20% |
| 2018-12-31 | -55.58% |
| 2018-09-30 | -36.30% |
| 2018-06-30 | -32.57% |
| 2018-03-31 | -27.45% |
| 2017-12-31 | -23.95% |
| 2017-09-30 | -31.56% |
| 2017-06-30 | -39.02% |
| 2017-03-31 | -31.69% |
| 2016-12-31 | -29.29% |
| 2016-09-30 | -26.59% |
| 2016-06-30 | -22.88% |
| 2016-03-31 | -43.50% |
| 2015-12-31 | -48.95% |
| 2015-09-30 | -41.36% |
| 2015-06-30 | -69.17% |
| 2015-03-31 | -80.68% |
| 2014-12-31 | -110.49% |
| 2014-09-30 | -90.96% |
| 2014-06-30 | -85.24% |
| 2014-03-31 | -17.39% |
| 2013-12-31 | -16.16% |
